Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically detailing increases in their personal holdings of ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed is the share price of £12.35 per ordinary share at the time of the transaction.
Material Changes
There are no material changes to the company's financial position or operations reported in this document. The filing solely documents an increase in share ownership by specific individuals following the re-investment of dividends paid on October 8, 2009.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Directors and senior managers increased their shareholdings via dividend re-investment at £12.35 per share.
- Specific individuals notified include Mr. A P Witty, Mrs. C M Witty, Mr. J S Heslop, Mr. D Learmouth, Dr. D Pulman, and Mrs. C R Pulman.
- The transaction was advised to the company and the individuals on October 12, 2009.
- This filing does not contain financial performance results for the period.